Sapyen and MSI Australia bring at-home post-vasectomy testing to more men

MSI Australia and Sapyen have launched a long-term partnership that lets vasectomy patients complete post-vasectomy semen analysis at home. The move targets a major follow-up gap in Australia, where up to 45% of men do not finish recommended testing.

Why it matters: - Up to 45% of Australian men do not complete the recommended post-vasectomy semen analysis, leaving an important step in care unfinished. - The new at-home testing option could reduce travel and timing barriers that keep patients from confirming their vasectomy was successful. - More completed follow-up tests could lower the risk of unrecognized procedure failure or ongoing pregnancy risk.

What happened: - Sapyen and MSI Australia entered a new long-term partnership. - MSI vasectomy clients can now choose to complete post-vasectomy semen analysis, or PVSA, at home through Sapyen. - The partnership applies to MSI Australia clients across its national vasectomy network. - The announcement was made in Melbourne on Sept. 23, 2026.

The details: - Clients can use the Sapyen Test Kit to produce a semen sample at home. - The sample is combined with Sapyen’s SPX72 preservation medium. - The sample is then returned to one of Sapyen’s partner accredited laboratories for analysis. - The model removes the need to travel to a pathology collection center and produce a sample within a narrow testing window. - MSI Australia will retain its clinical pathway and follow-up process for vasectomy patients. - MSI Australia is the country’s leading provider of sexual and reproductive healthcare and its largest independently accredited vasectomy provider. - MSI Australia operates twenty vasectomy clinics nationally. - MSI Australia says it has provided contraception and reproductive health services for more than 20 years. - MSI Australia says its Medical Director, Vasectomy Services, Dr. Justin Low, has performed more than 10,000 vasectomies. - Dr. Justin Low said Sapyen is a strong option for men who live remotely or who struggle with timing requirements for standard testing. - Low said Sapyen’s system provides monitoring from the start to the end of the PVSA process. - Sapyen says the partnership extends at-home semen diagnostics beyond fertility testing into other areas of male reproductive healthcare.

Between the lines: - The partnership targets a practical bottleneck, not the vasectomy procedure itself. - The biggest friction appears to be follow-up compliance, not demand for the procedure. - Medicare data reported in 2026 shows more than 36,000 vasectomies were performed nationally in 2025, up from 22,230 in 2015. - Sapyen founder and CEO Ash Ramachandran said greater convenience is expected to improve completion rates and the overall post-vasectomy experience. - The deal also fits MSI Australia’s broader emphasis on access and choice across reproductive healthcare.

What's next: - MSI clients will be able to use the at-home PVSA option as part of their post-vasectomy care. - Sapyen and MSI Australia are likely to watch whether the new workflow improves testing completion rates. - The partnership could become a model for other follow-up tests where convenience affects patient compliance.

The bottom line: - The partnership turns a common post-vasectomy follow-up task into an at-home process, aiming to make confirmation testing easier, faster and more likely to happen.